OBJECT DRUGS

Kinase Inhibitors:

• Acalabrutinib (Calquence)
• Bosutinib (Bosulif)
• Crizotinib (Xalkori)
• Dabrafenib (Tafinlar)
• Dasatinib (Sprycel)
• Erlotinib (Tarceva)
• Gefitinib (Iressa)
• Lapatinib (Tykerb)
• Neratinib (Nerlynx)
• Nilotinib (Tasigna)
• Pazopanib (Votrient)
• Sorafenib (Nexavar)

PRECIPITANT DRUGS

Gastric Antisecretory Agents:

• Cimetidine (Tagamet, etc.)
• Dexlansoprazole (Kapidex)
• Esomeprazole (Nexium, etc.)
• Famotidine (Pepcid, etc.)
• Lansoprazole (Prevacid, etc.)
• Nizatidine (Axid, etc.)
• Omeprazole (Prilosec, etc.)
• Pantoprazole (Protonix, etc.)
• Rabeprazole (Aciphex)
• Ranitidine (Zantac, etc.)

Comment:

Several kinase inhibitors are dependent on an acidic gastric pH for dissolution. Administration with antisecretory agents that increase gastric pH will reduce the bioavailability of the kinase inhibitor. Antacids may also interact.

Class 3: Assess Risk & Take Action if Necessary

• Monitor: Monitor for altered antineoplastic response if the gastric antisecretory agent is initiated, discontinued, or changed in dosage.